Drugs / YK1101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07139067 | Apr 2025 → Jul 2026 overdue | — | Peking University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YK1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07139067 ↗ |
| Modality | Cell therapy | “autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T)” NCT07139067 ↗ |
| Target | MAGEA4 | “T-cell receptor-engineered T cell (TCR-T) targeting melanoma-associated antigen-4 (MAGE-A4)” NCT07139067 ↗ |